Skip to content
    HCAT
    Earnings call· Jun 2026(Q2 FY26)

    Health Catalyst Q2 FY26 earnings call HCAT

    Aug 6, 2026 Source

    Executive summary

    Health Catalyst Q2 FY26 — Vitalware Divestiture and Debt Repayment Drive Strategic Focus

    Health Catalyst executed a pivotal strategic move in Q2 FY26 by divesting Vitalware for $147 million, enabling the full repayment of $160 million in credit facility debt and eliminating significant annual interest expenses. This action, part of the multi-year Project Nexus transformation, positions the company as debt-free with a strong balance sheet, allowing for focused investment in core technology opportunities and AI initiatives. While the company navigates near-term revenue headwinds from platform migrations and services work, management is prioritizing long-term value creation through disciplined investments and operational efficiency.

    Highlights

    5

    • Q2 total revenue of $70.5 million exceeded the high end of guidance ($68 million to $70 million).

    • Q2 adjusted EBITDA of $9.9 million came in at the high end of guidance ($9 million to $10 million).

    • Divested Vitalware for $147 million in cash, with net proceeds of $145.5 million.

    • Fully repaid approximately $160 million in credit facility debt, eliminating $19 million in annual GAAP interest expense.

    • Project Nexus is on track to exceed its original cost savings target.

    Concerns

    5

    • Migration-related churn headwinds are expected to continue through the end of 2027, with $12.5 million of notified ARR down-sell and churn identified.

    • Significant pressure in client retention work related to DOS to Ignite migration, with $52 million of additional at-risk ARR.

    • Anticipate exiting the year with services revenue closer to $55 million annually, at the lower end of the previously discussed range.

    • Overall adjusted gross margin is expected to come in below 50% for the full year, impacted by the Vitalware divestiture and migration costs.

    • Adjusted technology gross margin is expected to finish the year in the low 60s, slightly below prior communication.

    Guidance & targets

    12
    CategoryTargetConfidence
    Full-year 2026 Total Revenue
    $246 million to $249 million
    high materiality
    High
    Full-year 2026 Adjusted EBITDA
    $18 million to $18.5 million
    high materiality
    High
    Q3 2026 Total Revenue
    $55 million to $56 million
    medium materiality
    High
    Q3 2026 Adjusted EBITDA
    breakeven to $500,000
    medium materiality
    High
    Full-year Adjusted Gross Margin
    below 50%
    medium materiality
    Medium
    Full-year Adjusted Technology Gross Margin
    low 60s
    medium materiality
    Medium
    Full-year Adjusted Professional Services Gross Margin
    low to mid-teens
    medium materiality
    Medium
    Project Nexus Cost Savings
    lower end of original $3 million to $4 million estimate
    medium materiality
    High
    Full-year Stock-Based Compensation as % of Revenue
    mid-single digits
    low materiality
    High
    Migration-Related Churn Headwinds
    generally be through by the end of 2027
    high materiality
    Medium
    Annual Services Revenue Exit Rate
    closer to $55 million annually
    medium materiality
    Medium
    Full-year Bookings Target
    $22 million to $26 million
    medium materiality
    High

    Operational metrics

    16
    Total Revenue
    $70.5 millionExceeded high end of $68 million to $70 million guidance
    Q2 FY26

    Exceeded the high end of guided range.

    Technology Revenue
    $48.8 million
    Q2 FY26

    null

    Professional Services Revenue
    $21.7 million
    Q2 FY26

    null

    Adjusted Gross Margin
    51%Up from 50% in prior year period
    Q2 FY26

    null

    Adjusted Technology Gross Margin
    63%Down from 66% in prior year period
    Q2 FY26

    Reflects costs associated with migrating clients to Ignite and deployment costs incurred prior to revenue recognition.

    Adjusted Professional Services Gross Margin
    22%Up from 18% in prior year period
    Q2 FY26

    null

    Adjusted Operating Expenses
    $25.9 millionDown from $30.6 million in prior year period
    Q2 FY26

    Compared to 38% of revenue in the prior year period. Project Nexus savings partially reflected.

    Adjusted Net Income Per Share
    $0.04
    Q2 FY26

    null

    Cash, Cash Equivalents and Short-Term Investments
    $103.4 millionDown slightly from the first quarter, but still above where we ended last year
    Q2 FY26

    null

    Credit Facility Debt Repaid
    $160 million
    Q2 FY26

    Fully repaid using Vitalware divestiture proceeds and cash on hand.

    Annual GAAP Interest Expense Eliminated
    $19 million
    Annual

    Based on annualizing the first half of 2026.

    Annual Cash Interest Payments Eliminated
    $16.5 million
    Annual

    Based on annualizing the first half of 2026.

    Pro Forma Cash, Cash Equivalents and Short-Term Investments
    $82 million
    Q2 FY26

    Giving effect to the Vitalware transaction and credit facility repayment, with zero debt.

    Vitalware First Half Adjusted EBITDA
    $11.4 million
    H1 FY26

    Vitalware was a higher adjusted EBITDA margin business, though this elevated margin was not expected to continue.

    Notified ARR Down-sell and Churn (Migration-Related)
    $12.5 million
    Ongoing

    Related to DOS to Ignite migration.

    At-Risk ARR (Migration-Related)
    $52 millionExpected to retain $22 million of this
    Ongoing

    Related to DOS to Ignite migration.

    Industry KPIs

    3
    MetricValueDetails
    Adjusted EBITDA$9.9 millionUSD
    Bookings billings growth$22 million to $26 millionUSD
    Revenue adjusted EBITDA guidanceRevenue: $246 million to $249 million; Adjusted EBITDA: $18 million to $18.5 millionUSD

    Deals & partnerships

    1
    Med-MetrixDivestiture of Vitalware business$147 million in total cash consideration

    Subject to customary adjustments. A transition services agreement is in place for up to 6 months, providing a modest income offset.

    Risks & headwinds

    4
    Client Migrations and Associated ChurnExpected to generally be through by the end of 2027

    $12.5 million of notified ARR down-sell and churn related to DOS to Ignite migration; $52 million of additional at-risk ARR identified, with only $22 million expected to be retained.

    Mitigation: Continued client-by-client retention work; deliberate investments in Ignite and interoperability platform.

    Pressure on Services RevenueFY26 exit rate

    Anticipate exiting the year closer to $55 million in services revenue annually, at the lower end of the previously discussed range.

    Mitigation: Evaluating this part of the business and aligning it to highest areas of conviction, focusing on services in partnership with technology.

    Market Pressures on Health SystemsStructural, not cyclical, and increasingly urgent.

    Eroding margins, less favorable payer mix, rising labor and clinical costs.

    Mitigation: Positioning intelligence products and expertise to help systems reduce costs, improve clinical quality, accelerate ambulatory growth, and win consumers.

    Gross Margin CompressionFull year 2026

    Overall adjusted gross margin expected to be below 50% for the full year; adjusted technology gross margin in the low 60s (slightly below prior communication).

    Mitigation: Shifting revenue mix towards technology over the long-term; managing costs associated with migrations (duplicate hosting, data loading).

    What to watch in Q3 FY26

    5

    Migration-Related Churn Headwinds

    Next quarter and through end of 2027
    Current$12.5 million notified ARR down-sell/churn; $52 million at-risk ARR (expect to retain $22 million)
    TargetProgress towards being generally through by end of 2027

    Why it matters

    This represents a significant revenue headwind that needs to abate for the company to return to growth.

    As we've said before, we expect to generally be through the migration-related churn headwinds by the end of 2027.

    Q&A highlights

    2

    Clarify if the updated revenue and EBITDA guidance is solely due to the Vitalware divestiture or if other factors are at play.

    Jason Alger confirmed that the revenue guidance update was a direct reflection of Vitalware's removal. For EBITDA, while Vitalware's removal was the biggest driver, it also reflected deliberate investments in team members and core products.

    “Yes, as we look at revenue, it was a direct reflection of the removal of Vitalware from the guidance. ... And then from an EBITDA standpoint, similarly, the biggest driver was the removal of the Vitalware EBITDA contribution. Our EBITDA also reflects certain deliberate investments that we are making in our team members as well as in those core products that we discussed, including the intelligence products.”

    asked by Unknown Analyst · answered by Jason Alger

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Repositioning and Debt Elimination

    Health Catalyst completed the divestiture of its Vitalware business on July 31, 2026, for $147 million in total cash consideration, with net proceeds of $145.5 million. These proceeds, combined with cash on hand, were used to fully repay approximately $160 million in credit facility debt. This strategic move, part of 'Project Nexus,' eliminates roughly $19 million in annual GAAP interest expense and $16.5 million in annual cash interest payments, positioning the company as debt-free and providing financial flexibility for future investments.

    02

    Focus on Core Technology and AI Initiatives

    The divestiture allows Health Catalyst to concentrate on its highest conviction technology opportunities, particularly intelligence products that pair analytics and expertise with improvement agents. The company is deliberately investing in new products, proprietary intelligence layers, AI-driven automation, and the continued build-out of its Ignite and interoperability platform. This focus aims to address structural challenges faced by health systems, such as eroding margins and rising costs, through data-driven insights and solutions.

    03

    Market Challenges and Client Needs

    Health systems are under immense pressure from eroding margins, a less favorable payer mix, and rising labor and clinical costs. Management emphasized that these challenges are structural, not cyclical, and require urgent action to reduce costs, improve clinical quality, accelerate ambulatory growth, and win consumers. Health Catalyst believes its deep domain expertise and 18 years of improvement data position it well to help clients navigate these pressing areas of need.

    04

    Multi-Year Transformation and Near-Term Headwinds

    The company is in the early stages of a multi-year transformation, acknowledging both enthusiasm for its strategic direction and ongoing revenue headwinds. These headwinds are primarily related to platform migrations (DOS to Ignite) and lower-margin services work. Management expects migration-related churn to generally subside by the end of 2027, with some churn, including associated services revenue, pulling forward into the second half of 2026, impacting near-term numbers.

    05

    Operational Efficiency and Cost Management (Project Nexus)

    Project Nexus, a strategic initiative designed to fundamentally transform the operating model, is tracking to plan and is expected to exceed its original cost savings target. However, net savings are slightly reduced to the lower end of the original $3 million to $4 million estimate due to intentional investments in team member retention and motivation during this period of significant transition. The company also continues to make progress in reducing stock-based compensation, targeting mid-single digits as a percentage of revenue for FY26.

    06

    Gross Margin Dynamics and Investment in Migrations

    Overall adjusted gross margin is expected to be below 50% for the full year, primarily due to the divestiture of the higher-margin Vitalware business. Adjusted technology gross margin is projected to be in the low 60s, impacted by costs associated with client migrations to Ignite, duplicate hosting, and heavy data loading for HIE client deployments. Adjusted professional services gross margin is expected to finish in the low to mid-teens, also affected by migrations, but consistent with prior commentary.

    AI-generated summary of the company’s earnings call. Not investment advice.